BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 22920907)

  • 1. Hsp90 inhibitors as anti-cancer agents, from basic discoveries to clinical development.
    Soga S; Akinaga S; Shiotsu Y
    Curr Pharm Des; 2013; 19(3):366-76. PubMed ID: 22920907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hsp90 molecular chaperone inhibitors: are we there yet?
    Neckers L; Workman P
    Clin Cancer Res; 2012 Jan; 18(1):64-76. PubMed ID: 22215907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HSP90 inhibitors: current development and potential in cancer therapy.
    Sidera K; Patsavoudi E
    Recent Pat Anticancer Drug Discov; 2014 Jan; 9(1):1-20. PubMed ID: 23312026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents.
    Miyata Y
    Curr Pharm Des; 2005; 11(9):1131-8. PubMed ID: 15853661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heat shock protein 90 inhibitors as therapeutic agents.
    Gomez-Monterrey I; Sala M; Musella S; Campiglia P
    Recent Pat Anticancer Drug Discov; 2012 Sep; 7(3):313-36. PubMed ID: 22338602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions.
    Hong DS; Banerji U; Tavana B; George GC; Aaron J; Kurzrock R
    Cancer Treat Rev; 2013 Jun; 39(4):375-87. PubMed ID: 23199899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent Advances in the Discovery of Novel HSP90 Inhibitors: An Update from 2014.
    Xiao Y; Liu Y
    Curr Drug Targets; 2020; 21(3):302-317. PubMed ID: 31465284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current Understanding of HSP90 as a Novel Therapeutic Target: An Emerging Approach for the Treatment of Cancer.
    Haque A; Alam Q; Alam MZ; Azhar EI; Sait KH; Anfinan N; Mushtaq G; Kamal MA; Rasool M
    Curr Pharm Des; 2016; 22(20):2947-59. PubMed ID: 27013225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery and development of purine-scaffold Hsp90 inhibitors.
    Chiosis G
    Curr Top Med Chem; 2006; 6(11):1183-91. PubMed ID: 16842155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-intrinsic and tumor-extrinsic factors impacting hsp90- targeted therapy.
    Alarcon SV; Mollapour M; Lee MJ; Tsutsumi S; Lee S; Kim YS; Prince T; Apolo AB; Giaccone G; Xu W; Neckers LM; Trepel JB
    Curr Mol Med; 2012 Nov; 12(9):1125-41. PubMed ID: 22804236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticancer Inhibitors of Hsp90 Function: Beyond the Usual Suspects.
    Garg G; Khandelwal A; Blagg BS
    Adv Cancer Res; 2016; 129():51-88. PubMed ID: 26916001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress.
    Workman P; Burrows F; Neckers L; Rosen N
    Ann N Y Acad Sci; 2007 Oct; 1113():202-16. PubMed ID: 17513464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in Hsp90 inhibitors as antitumor agents.
    Messaoudi S; Peyrat JF; Brion JD; Alami M
    Anticancer Agents Med Chem; 2008 Oct; 8(7):761-82. PubMed ID: 18855578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heat-shock protein 90 inhibitors in antineoplastic therapy: is it all wrapped up?
    Isaacs JS
    Expert Opin Investig Drugs; 2005 Jun; 14(6):569-89. PubMed ID: 16004589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyond.
    Georgakis GV; Younes A
    Future Oncol; 2005 Apr; 1(2):273-81. PubMed ID: 16555999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents.
    Chiosis G; Caldas Lopes E; Solit D
    Curr Opin Investig Drugs; 2006 Jun; 7(6):534-41. PubMed ID: 16784024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using natural product inhibitors to validate Hsp90 as a molecular target in cancer.
    Neckers L
    Curr Top Med Chem; 2006; 6(11):1163-71. PubMed ID: 16842153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heat-shock protein 90: potential involvement in the pathogenesis of malignancy and pharmacological intervention.
    Ochel HJ; Gademann G
    Onkologie; 2002 Oct; 25(5):466-73. PubMed ID: 12415202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibiting protein-protein interactions of Hsp90 as a novel approach for targeting cancer.
    Dutta Gupta S; Bommaka MK; Banerjee A
    Eur J Med Chem; 2019 Sep; 178():48-63. PubMed ID: 31176095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Old and New Approaches to Target the Hsp90 Chaperone.
    Sanchez J; Carter TR; Cohen MS; Blagg BSJ
    Curr Cancer Drug Targets; 2020; 20(4):253-270. PubMed ID: 31793427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.